Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV Protease Inhibitor

   Ascletis Gains China Market Rights from Janssen to a Clinical Stage HIV
                              Protease Inhibitor

-- TMC310911 is Third Product in Growing Ascletis Pipeline of Infectious
Disease and Cancer Therapeutics --

PR Newswire

HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013

HANGZHOU, China and RESEARCH TRIANGLE PARK, N.C., April 30, 2013 /PRNewswire/
-- Ascletis today announced that the company has licensed development,
manufacturing and commercialization rights from Janssen R&D Ireland to
TMC310911, a next-generation HIV protease inhibitor (PI). The agreement
provides Ascletis with exclusive rights to develop and commercialize TMC310911
in Greater China, including mainland China and Macau. Janssen will retain all
rights in the rest of the world and is eligible to receive royalties based on
product sales in Greater China.

(Logo: http://photos.prnewswire.com/prnh/20130410/MM92788LOGO)

"This licensing agreement for TMC310911 adds a third drug candidate in
late-stage development to the Ascletis pipeline, which aims to provide
innovative therapeutics for important medical needs in China," said Jinzi J.
Wu, Ph.D., Ascletis President and Chief Executive Officer. "Based on research
to date, we believe that TMC310911 has the potential to offer a new
standard-of-care, especially for HIV-infected patients exhibiting multi-drug
resistance to current PIs."

Published research has shown that TMC310911 offers a higher genetic barrier to
the development of resistance than any existing HIV PIs. TMC310911 also
exhibits broader activity against multi-PI resistant recombinant clinical
isolates of HIV than any currently approved PI, including darunavir, the
current standard of care. Moreover, three clinical studies completed by
Janssen, including a Phase 2a study, showed TMC310911 to have a favorable
safety and tolerability profile and demonstrated clinical proof-of-concept in
treatment naïve, HIV positive patients.

About Ascletis

Ascletis is an emerging biotechnology company, dedicated to discovering,
developing and commercializing important new treatments for cancer and
infectious diseases. Ascletis is focused on clinical development of innovative
medicines and commercialization for the growing Chinese pharmaceutical
marketplace. Ascletis has assembled an entrepreneurial management and senior
scientific team with a track record of successful pharmaceutical discovery and
development at major global pharmaceutical and emerging biotechnology
companies in the United States and Europe. To date the company has added three
late-stage candidates to its product portfolio: ASC-06 (ALN-VSP), a clinical
stage, first-in-class, systemically delivered RNAi therapeutic for the
treatment of liver cancers partnered with Alnylam Pharmaceuticals, Inc.;
ASC-08 (danoprevir), a clinical stage hepatitis C protease inhibitor partnered
with Roche; and ASC-09 (TMC310911), a next-generation HIV protease inhibitor
acquired from Janssen, a pharmaceutical company of Johnson & Johnson. For more
information, please visit www.ascletis.com outside China or
www.ascletis.com.cn inside China.

SOURCE Ascletis

Website: http://www.ascletis.com
Contact: Ascletis: Jinzi J. Wu, Ph.D., President and CEO, US: +1 919 328 0212,
China: +86 150 8876 9922, jinzi.wu@ascletis.com; Media: Joan Kureczka,
Kureczka-Martin Associates, 415-821-2413, Joan@kureczka-martin.com
 
Press spacebar to pause and continue. Press esc to stop.